Evidence map›Paper›PMID 42657886›Full record

ArticleJournal of virology2026

HSV-1 LAT promotes ocular diseases in the absence of type I IFN responses in sensory neurons.

Shaohui Wang, Ujjaldeep Jaggi, Jay J Oh, Deepak Arya, Homayon Ghiasi

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shaohui WangDepartment of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.ORCID 0000-0001-7764-0581
Ujjaldeep JaggiDepartment of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.
Jay J OhDepartment of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.
Deepak AryaDepartment of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.
Homayon GhiasiDepartment of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.ORCID 0000-0003-3291-1995

Funding

Ocular HSV: Mechanism of virus reactivationR01EY029160 · NEI · CEDARS-SINAI MEDICAL CENTER · PI HOMAYON GHIASI · 2018 to 2026
$3.4M
Role of type 1 IFN in eye infectionR01EY033574 · NEI · CEDARS-SINAI MEDICAL CENTER · PI HOMAYON GHIASI · 2023 to 2026
$1.9M
NEI NIH HHS R01 EY029160NEI NIH HHS R01 EY033574NEI NIH HHS RO1EY029160NEI NIH HHS RO1EY033574
6 · The paper itself

Abstract

Type I interferons (IFNs) are a critical first line of antiviral defense during herpes simplex virus type 1 (HSV-1) infection. In mice, the type I IFN family includes at least 14 IFNα subtypes and a single IFNβ, each of which signals through the common receptor, IFNαβR. We previously reported that deletion of a single IFNα subtype (IFNα2A

Indexed as

Herpes SimplexHerpesvirus 1, HumanInterferon Type ISensory Receptor CellsAnimalsMiceMice, KnockoutMicroRNAsReceptor, Interferon alpha-betaSignal TransductionVirus LatencyVirus ReplicationIfnar1 protein, mouseInterferon Type Ilatency associated transcript, herpes simplex virus-1MicroRNAsReceptor, Interferon alpha-betaCD8exhaustioneye diseaseIFNAR1 conditionallatencyocular infectionPD-1reactivationtype I interferonvirus replication

Identifiers

PMID42657886
PMCPMC13595914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.